CDK4/6 inhibitor ribociclib induces cardiotoxicity in dynamic engineered heart tissues, mitigated by E2F1 overexpression

13 April 2024 (17:25 - 17:40)

Organised by:

Abstract

Sign in to view the resources

Slides

About the speaker

Mr Itamar Dias

University Medical Centre Groningen, Groningen (Netherlands (The))

3 More presentations in this session

Presentation thumbnail

Cardioprotection via modulation of the immune response

Doctor Z. Varga (Budapest, HU)

Presentation thumbnail

Cancer therapies and vascular toxicities

Professor I. Andreadou (Athens, GR)

Presentation thumbnail

Accelerated atherosclerosis by immune checkpoint inhibitors

Doctor N. Van Es (Amsterdam, NL)

Access the full session

Session thumbnail

The immune system in the pathogenesis and treatment of cancer therapy-induced cardiovascular toxicity

The Event

Event poster

Frontiers in CardioVascular Biomedicine 2024

13 April 2024 17:25 CET

You may be interested in

Congress Presentation

CDK4/6 inhibitor ribociclib induces cardiotoxicity in dynamic engineered heart tissues, mitigated by E2F1 overexpression

14 May 2024

Congress Presentation

Direct effects of the tyrosine kinase inhibitors (TKIs) nilotinib and imatinib on the myocardium: clues towards cardiotoxic profiles

20 June 2025

Congress Presentation

Atrial arrhythmia associated with cdk4/6 inhibitor use in patients with hormone receptor-positive / HER2-negative breast cancer

20 June 2025

ESC Journals

Cardio-protective effect of trimetazidine in patients with disseminated breast cancer

24 May 2023

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources